Screener
Iovance Biotherapeutics, Inc. IOVA Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other liabilities | 77,964 | 111,156 |
| Note payable - current | — | 1,000 |
| Operating lease liabilities | 2,673 | 4,043 |
| Total Current Liabilities | 106,848 | 138,358 |
| Non-Current Liabilities | ||
| Operating lease liabilities – non-current | 43,330 | 44,401 |
| Deferred tax liabilities | 29,308 | 31,828 |
| Total Non-Current Liabilities | 72,638 | 76,229 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s total current liabilities?
- Iovance Biotherapeutics, Inc. (IOVA) reported total current liabilities of $106.85M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s total current liabilities changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total current liabilities decreased by 17.3% year-over-year, from $129.16M to $106.85M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s total current liabilities has grown at a 20.3% compound annual growth rate (CAGR), from $54.87M to $138.36M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Iovance Biotherapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude